drugset / Trial / NCT05883852
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients
Timeline
- Start
- 2023-06-07
- Primary completion
- 2031-07-01
- Completion
- 2031-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Epirubicin | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |